ProfileGDS5678 / 1455581_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 68% 69% 77% 67% 55% 52% 65% 67% 68% 69% 71% 66% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2487369
GSM967853U87-EV human glioblastoma xenograft - Control 24.1233768
GSM967854U87-EV human glioblastoma xenograft - Control 34.2197869
GSM967855U87-EV human glioblastoma xenograft - Control 45.4382477
GSM967856U87-EV human glioblastoma xenograft - Control 54.0632967
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.461655
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3528452
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9336165
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0501667
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1434368
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2345269
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4773971
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9651866
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1054568